SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (4398)5/24/2003 8:36:46 AM
From: Qualified Opinion  Read Replies (1) | Respond to of 10345
 
Erik, have you compared Remicade(JNJ) to Antegren for Crohn's ?



To: Icebrg who wrote (4398)5/24/2003 8:59:21 AM
From: William Partmann  Read Replies (1) | Respond to of 10345
 
No, I understood, your comment was directed at my thoughts and predictions. So I was clarifying the I think KM is not a failure even though I was against his ilk as CEO. Again, when I wrote that, I wasn't thinking about the option of selling the company. So in the context of running and growing a drug company, KM was not the right person.

Whether you break even depends upon Antegren, IMO.

Bill


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News